C

CytoTools AG
XETRA:T5O

Watchlist Manager
CytoTools AG
XETRA:T5O
Watchlist
Price: 101.26 EUR 0.98% Market Closed
Market Cap: 52.8m EUR
Have any thoughts about
CytoTools AG?
Write Note

Intrinsic Value

T5O doesn't have a meaningful market cap.

The intrinsic value of one T5O stock under the Base Case scenario is 152 EUR. Compared to the current market price of 101.26 EUR, CytoTools AG is Undervalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

T5O Intrinsic Value
152 EUR
Undervaluation 33%
Intrinsic Value
Price
C
Base Case Scenario

Valuation Backtest
CytoTools AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for T5O cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about T5O?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about CytoTools AG

Provide an overview of the primary business activities
of CytoTools AG.

What unique competitive advantages
does CytoTools AG hold over its rivals?

What risks and challenges
does CytoTools AG face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for CytoTools AG.

Provide P/S
for CytoTools AG.

Provide P/E
for CytoTools AG.

Provide P/OCF
for CytoTools AG.

Provide P/FCFE
for CytoTools AG.

Provide P/B
for CytoTools AG.

Provide EV/S
for CytoTools AG.

Provide EV/GP
for CytoTools AG.

Provide EV/EBITDA
for CytoTools AG.

Provide EV/EBIT
for CytoTools AG.

Provide EV/OCF
for CytoTools AG.

Provide EV/FCFF
for CytoTools AG.

Provide EV/IC
for CytoTools AG.

Show me price targets
for CytoTools AG made by professional analysts.

What are the Revenue projections
for CytoTools AG?

How accurate were the past Revenue estimates
for CytoTools AG?

What are the Net Income projections
for CytoTools AG?

How accurate were the past Net Income estimates
for CytoTools AG?

What are the EPS projections
for CytoTools AG?

How accurate were the past EPS estimates
for CytoTools AG?

What are the EBIT projections
for CytoTools AG?

How accurate were the past EBIT estimates
for CytoTools AG?

Compare the revenue forecasts
for CytoTools AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of CytoTools AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of CytoTools AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of CytoTools AG compared to its peers.

Compare the P/E ratios
of CytoTools AG against its peers.

Discuss the investment returns and shareholder value creation
comparing CytoTools AG with its peers.

Analyze the financial leverage
of CytoTools AG compared to its main competitors.

Show all profitability ratios
for CytoTools AG.

Provide ROE
for CytoTools AG.

Provide ROA
for CytoTools AG.

Provide ROIC
for CytoTools AG.

Provide ROCE
for CytoTools AG.

Provide Gross Margin
for CytoTools AG.

Provide Operating Margin
for CytoTools AG.

Provide Net Margin
for CytoTools AG.

Provide FCF Margin
for CytoTools AG.

Show all solvency ratios
for CytoTools AG.

Provide D/E Ratio
for CytoTools AG.

Provide D/A Ratio
for CytoTools AG.

Provide Interest Coverage Ratio
for CytoTools AG.

Provide Altman Z-Score Ratio
for CytoTools AG.

Provide Quick Ratio
for CytoTools AG.

Provide Current Ratio
for CytoTools AG.

Provide Cash Ratio
for CytoTools AG.

What is the historical Revenue growth
over the last 5 years for CytoTools AG?

What is the historical Net Income growth
over the last 5 years for CytoTools AG?

What is the current Free Cash Flow
of CytoTools AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for CytoTools AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
CytoTools AG

Current Assets 1.2m
Cash & Short-Term Investments 1.1m
Receivables 50.5k
Other Current Assets 45.2k
Non-Current Assets 20.2m
Long-Term Investments 20.2m
PP&E 660
Other Non-Current Assets 2.7k
Current Liabilities 59.6k
Accounts Payable 47.9k
Other Current Liabilities 11.7k
Non-Current Liabilities 170.8k
Other Non-Current Liabilities 170.8k
Efficiency

Earnings Waterfall
CytoTools AG

Revenue
20.5k EUR
Operating Expenses
-706k EUR
Operating Income
-685.5k EUR
Other Expenses
24.8k EUR
Net Income
-660.7k EUR

Free Cash Flow Analysis
CytoTools AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

T5O Profitability Score
Profitability Due Diligence

CytoTools AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

25/100
Profitability
Score

CytoTools AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

T5O Solvency Score
Solvency Due Diligence

CytoTools AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

CytoTools AG's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

T5O Price Targets Summary
CytoTools AG

Wall Street analysts forecast T5O stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for T5O is 25.93 EUR with a low forecast of 25.68 EUR and a high forecast of 26.7 EUR.

Lowest
Price Target
25.68 EUR
75% Downside
Average
Price Target
25.93 EUR
74% Downside
Highest
Price Target
26.7 EUR
74% Downside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for T5O?

Click here to dive deeper.

Dividends

CytoTools AG
does not pay dividends
Shareholder Yield

Current shareholder yield for T5O is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

CytoTools AG

Country

Germany

Industry

Biotechnology

Market Cap

52.8m EUR

Dividend Yield

0%

Description

CytoTools AG is a biotechnology company, which engages in the research and development of therapies to treat cause of diseases. The company is headquartered in Darmstadt, Hessen and currently employs 1 full-time employees. The company went IPO on 2007-05-18. The firm holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. CytoTools AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections, and pre-clinical stage CardioClean for the treatment of restenosis, diabetis and carotis-stenosis.

Contact

HESSEN
Darmstadt
Klappacher Strasse 126
+4961519515812.0
cytotools.de

IPO

2007-05-18

Employees

1

Officers

Chief Executive Officer
Dr. Mark-André Freyberg
Co-Founder & Chief Research Officer
Dr. Dirk Kaiser
Member of Executive Board
Dr. Bruno Rosen

See Also

Discover More
What is the Intrinsic Value of one T5O stock?

The intrinsic value of one T5O stock under the Base Case scenario is 152 EUR.

Is T5O stock undervalued or overvalued?

Compared to the current market price of 101.26 EUR, CytoTools AG is Undervalued by 33%.

Back to Top